HomeESPR • NASDAQ
add
Esperion Therapeutics Inc
Previous close
$1.64
Day range
$1.64 - $1.71
Year range
$0.70 - $3.40
Market cap
330.64M USD
Avg Volume
3.26M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 73.83M | 186.33% |
Operating expense | 44.18M | 30.11% |
Net income | -61.92M | -24.01% |
Net profit margin | -83.87 | 56.69% |
Earnings per share | -0.05 | 89.99% |
EBITDA | 2.58M | 106.98% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 189.30M | 36.71% |
Total assets | 352.32M | 50.16% |
Total liabilities | 696.54M | 14.83% |
Total equity | -344.22M | — |
Shares outstanding | 196.22M | — |
Price to book | -0.93 | — |
Return on assets | 1.78% | — |
Return on capital | 7.18% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -61.92M | -24.01% |
Cash from operations | -7.20M | 70.89% |
Cash from investing | -77.00K | -100.44% |
Cash from financing | -30.02M | -3,811.12% |
Net change in cash | -37.30M | -479.18% |
Free cash flow | 33.78M | 281.39% |
About
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Wikipedia
Founded
May 1998
Headquarters
Website
Employees
240
